期刊
DISEASE MODELS & MECHANISMS
卷 14, 期 10, 页码 -出版社
COMPANY BIOLOGISTS LTD
DOI: 10.1242/dmm.049018
关键词
Tuberculosis; Host-directed therapy; Rapamycin; Inflammation
资金
- National Institute of Allergy and Infectious Disease [UH2AI122313]
- National Institute of Allergy and Infectious Diseases [R37AI042999, R01AI111935]
- National Institute of General Medical Sciences center grant [P20GM121176]
The study found that rapamycin may be a candidate adjunct therapy for tuberculosis treatment, reducing infection-induced lung inflammation and the number and size of granulomas. The results suggest the potential use of rapamycin and its analogs as adjunct TB therapies.
Tuberculosis (TB) treatment regimens are lengthy, causing non-adherence to treatment. Inadequate treatment can lead to relapse and the development of drug resistance TB. Furthermore, patients often exhibit residual lung damage even after cure, increasing the risk for relapse and development of other chronic respiratory illnesses. Host-directed therapeutics are emerging as an attractive means to augment the success of TB treatment. In this study, we used C3HeB/FeJ mice as an experimental model to investigate the potential role of rapamycin, a mammalian target of rapamycin inhibitor, as an adjunctive therapy candidate during the treatment of Mycobacterium tuberculosis infection with moxifloxacin. We report that administration of rapamycin with or without moxifloxacin reduced infection-induced lung inflammation, and the number and size of caseating necrotic granulomas. Results from this study strengthen the potential use of rapamycin and its analogs as adjunct TB therapy, and importantly underscore the utility of the C3HeB/FeJ mouse model as a preclinical tool for evaluating host-directed therapy candidates for the treatment of TB.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据